INTRODUCTION: The reasons that some smokers find it harder to quit than others are unclear. Understanding how individual differences predict smoking cessation outcomes may allow the development of more successful personalized treatments for nicotine dependence. Theoretical models suggest that drug users might be characterized by increased sensitivity to drug cues and by reduced sensitivity to nondrug-related natural rewards. We hypothesized that baseline differences in brain sensitivity to natural rewards and cigarette-related cues would predict the outcome of a smoking cessation attempt. METHODS: Using functional magnetic resonance imaging, we recorded prequit brain responses to neutral, emotional (pleasant and unpleasant), and cigarette-related cues from 55 smokers interested in quitting. We then assessed smoking abstinence, mood, and nicotine withdrawal symptoms during the course of a smoking cessation attempt. RESULTS: Using cluster analysis, we identified 2 groups of smokers who differed in their baseline responses to pleasant cues and cigarette-related cues in the posterior visual association areas, the dorsal striatum, and the medial and dorsolateral prefrontal cortex. Smokers who showed lower prequit levels of brain reactivity to pleasant stimuli than to cigarette-related cues were less likely to be abstinent 6 months after their quit attempt, and they had higher levels of negative affect during the course of the quit attempt. CONCLUSIONS: Smokers with blunted brain responses to pleasant stimuli, relative to cigarette-related stimuli, had more difficulty quitting smoking. For these individuals, the lack of alternative forms of reinforcement when nicotine deprived might be an important factor underlying relapse. Normalizing these pathological neuroadaptations may help them achieve abstinence.
INTRODUCTION: The reasons that some smokers find it harder to quit than others are unclear. Understanding how individual differences predict smoking cessation outcomes may allow the development of more successful personalized treatments for nicotine dependence. Theoretical models suggest that drug users might be characterized by increased sensitivity to drug cues and by reduced sensitivity to nondrug-related natural rewards. We hypothesized that baseline differences in brain sensitivity to natural rewards and cigarette-related cues would predict the outcome of a smoking cessation attempt. METHODS: Using functional magnetic resonance imaging, we recorded prequit brain responses to neutral, emotional (pleasant and unpleasant), and cigarette-related cues from 55 smokers interested in quitting. We then assessed smoking abstinence, mood, and nicotine withdrawal symptoms during the course of a smoking cessation attempt. RESULTS: Using cluster analysis, we identified 2 groups of smokers who differed in their baseline responses to pleasant cues and cigarette-related cues in the posterior visual association areas, the dorsal striatum, and the medial and dorsolateral prefrontal cortex. Smokers who showed lower prequit levels of brain reactivity to pleasant stimuli than to cigarette-related cues were less likely to be abstinent 6 months after their quit attempt, and they had higher levels of negative affect during the course of the quit attempt. CONCLUSIONS: Smokers with blunted brain responses to pleasant stimuli, relative to cigarette-related stimuli, had more difficulty quitting smoking. For these individuals, the lack of alternative forms of reinforcement when nicotine deprived might be an important factor underlying relapse. Normalizing these pathological neuroadaptations may help them achieve abstinence.
Authors: Amy C Janes; Diego A Pizzagalli; Sarah Richardt; Blaise deB Frederick; Sarah Chuzi; Gladys Pachas; Melissa A Culhane; Avram J Holmes; Maurizio Fava; A Eden Evins; Marc J Kaufman Journal: Biol Psychiatry Date: 2010-02-20 Impact factor: 13.382
Authors: Jonathan P Dunning; Muhammad A Parvaz; Greg Hajcak; Thomas Maloney; Nelly Alia-Klein; Patricia A Woicik; Frank Telang; Gene-Jack Wang; Nora D Volkow; Rita Z Goldstein Journal: Eur J Neurosci Date: 2011-03-31 Impact factor: 3.386
Authors: Mark L Rubinstein; Tracy L Luks; Wendy Y Dryden; Michelle A Rait; Gregory V Simpson Journal: Nicotine Tob Res Date: 2011-03-31 Impact factor: 4.244
Authors: Francesco Versace; Jeffrey M Engelmann; Edward F Jackson; Vincent D Costa; Jason D Robinson; Cho Y Lam; Jennifer A Minnix; Victoria L Brown; David W Wetter; Paul M Cinciripini Journal: Eur J Neurosci Date: 2011-11-20 Impact factor: 3.386
Authors: Shelly B Flagel; Jeremy J Clark; Terry E Robinson; Leah Mayo; Alayna Czuj; Ingo Willuhn; Christina A Akers; Sarah M Clinton; Paul E M Phillips; Huda Akil Journal: Nature Date: 2010-12-08 Impact factor: 49.962
Authors: Simon Zhornitsky; Sheng Zhang; Jaime S Ide; Herta H Chao; Wuyi Wang; Thang M Le; Robert F Leeman; Jinbo Bi; John H Krystal; Chiang-Shan R Li Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2018-12-12
Authors: Francesco Versace; Jeffrey M Engelmann; Menton M Deweese; Jason D Robinson; Charles E Green; Cho Y Lam; Jennifer A Minnix; Maher A Karam-Hage; David W Wetter; Susan M Schembre; Paul M Cinciripini Journal: Nicotine Tob Res Date: 2017-06-01 Impact factor: 4.244
Authors: Travis T Nichols; Jonathan Foulds; Jessica M Yingst; Susan Veldheer; Shari Hrabovsky; John Richie; Thomas Eissenberg; Stephen J Wilson Journal: Brain Res Bull Date: 2015-10-23 Impact factor: 4.077
Authors: Maggie M Sweitzer; Charles F Geier; Merideth A Addicott; Rachel Denlinger; Bethany R Raiff; Jesse Dallery; F Joseph McClernon; Eric C Donny Journal: Neuropsychopharmacology Date: 2016-04-19 Impact factor: 7.853
Authors: Paul M Cinciripini; Charles E Green; Jason D Robinson; Maher Karam-Hage; Jeffrey M Engelmann; Jennifer A Minnix; David W Wetter; Francesco Versace Journal: Psychopharmacology (Berl) Date: 2017-03-08 Impact factor: 4.530
Authors: Sarah W Yip; Iris M Balodis; Kathleen M Carroll; Suchitra Krishnan-Sarin; Marc N Potenza Journal: Drug Alcohol Depend Date: 2016-08-21 Impact factor: 4.492